Vimarsana
Biggest News Aggregation in the World

Page 47 - Accessed March News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed March Today - Breaking & Trending Today

FDA Approves Oral Testosterone Replacement Therapy Tlando - Vimarsana News

FDA Approves Oral Testosterone Replacement Therapy Tlando

The FDA has approved Tlando (testosterone undecanoate), an oral testosterone replacement therapy for adult males.

FDA Approves Oral Testosterone Replacement Therapy Tlando - Vimarsana News

FDA Approves Oral Testosterone Replacement Therapy Tlando

The FDA has approved Tlando (testosterone undecanoate), an oral testosterone replacement therapy for adult males.

Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma - Vimarsana News

Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma

Breyanzi represents a differentiated CAR T cell therapy with demonstrated rapid and durable complete responses and a manageable safety profile Approval of Breyanzi is based on results from TRANSCEND

BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's Disease - Vimarsana News

BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's Disease

/PRNewswire/ -- NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation, announced positive, long-term safety and tolerability data...

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions - Vimarsana News

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial...